Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.

BMC cancer - 27 Mar 2018

Wang Yan, Zhang Shijia, Wu Fengying, Zhao Jing, Li Xuefei, Zhao Chao, Ren Shengxiang, Zhou Caicun

Abstract excerpt

BACKGROUND: HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study was to investigate the efficacy of first line chemotherapy in patients with advanced HER2-mutant lung adenocarcinomas....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Odds Ratio

Share to Pemetrexed

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 29587667
DOI: 10.1186/s12885-018-4277-x
PMCID: PMC5869778

Genes

ALK
ROS1
EGFR
KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.PMID 29587667Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.Semantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.Semantic proximity Read ↗

Second-Line Therapy for Advanced NSCLC.Semantic proximity Read ↗

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.Semantic proximity Read ↗

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.Semantic proximity Read ↗

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.